迪哲医药(688192) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 81,318,560.00[21] - The net profit attributable to shareholders of the listed company was a loss of RMB 224,234,890.87[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 254,748,635.69[21] - The basic and diluted earnings per share were both negative RMB 0.54[21] - Net profit for Q1 2024 was a loss of CNY 224,234,890.87, compared to a loss of CNY 239,523,659.32 in Q1 2023, showing a slight improvement[49] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.54, compared to CNY -0.59 in Q1 2023[50] Cash Flow - The net cash flow from operating activities was a negative RMB 126,071,888.78[21] - Net cash inflow from operating activities in Q1 2024 was CNY 125,113,639.21, compared to CNY 11,119,984.71 in Q1 2023[37] - Cash outflow from operating activities totaled $251,185,527.99, an increase from $214,333,920.75 in the previous period[53] - Net cash flow from operating activities was -$126,071,888.78, improving from -$203,213,936.04 year-over-year[53] - The total cash inflow from other operating activities in Q1 2024 was CNY 28,651,415.21, compared to CNY 5,548,147.78 in Q1 2023[37] Assets and Liabilities - Total assets amounted to RMB 1,552,238,258.99, an increase from RMB 1,496,378,567.44 in the previous period[16] - Total liabilities increased to RMB 855,645,592.62 from RMB 647,751,151.64[17] - Current assets totaled RMB 978,932,665.10, compared to RMB 910,361,387.23 in the previous period[16] - Non-current assets decreased to RMB 573,305,593.89 from RMB 586,017,180.21[16] - Equity attributable to shareholders decreased by 17.92% to ¥696,592,666.37 from ¥848,627,415.80 at the end of the previous year[22] Research and Development - Total R&D investment reached ¥204,770,425.91, representing a year-on-year increase of 30.75%[22] - Research and development expenses for Q1 2024 were CNY 204,770,425.91, up from CNY 156,614,796.50 in Q1 2023, indicating a 30.7% increase[47] Government Support - Government subsidies recognized in the current period amounted to ¥26,680,000.00, primarily from government support income[23] Shareholder Information - The total number of shareholders with voting rights was reported, with the top ten shareholders holding significant stakes[25] Cash and Cash Equivalents - The company’s cash and cash equivalents increased to ¥95,312,852.54 from ¥74,201,573.96 at the end of the previous year[30] - The ending balance of cash and cash equivalents increased to $95,037,852.54 from $85,008,536.02[54] - Total cash and cash equivalents increased by $21,111,278.58, contrasting with a decrease of $36,390,963.65 in the previous period[54] Operating Costs - Total operating costs for Q1 2024 were CNY 338,128,124.10, an increase from CNY 251,337,057.44 in Q1 2023, representing a 34.4% increase[47] - Sales expenses for Q1 2024 were CNY 91,500,983.93, compared to CNY 35,756,837.80 in Q1 2023, reflecting a 156.5% increase[47] Financial Investments - The company’s financial investments generated a fair value change gain of ¥3,833,744.82[22] Accumulated Deficit - The company reported an accumulated deficit of ¥2,737,799,757.84, compared to ¥2,513,564,866.97 in the previous year[33]